Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion
Brief Summary: Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.


Options:
A: Arm Label: CRVO Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: CRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: CRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: BRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): BRVO standard care, CRVO Observation | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 1 mg dose triamcinolone acetonide, CRVO 1 mg dose triamcinolone acetonide | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 4 mg dose triamcinolone acetonide, CRVO 4 mg dose triamcinolone acetonide
B: Arm Label: 1-ranibizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: 2-ranibizumab with laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: 3-laser monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 1-ranibizumab monotherapy, 2-ranibizumab with laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): 2-ranibizumab with laser, 3-laser monotherapy
C: Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of bevacizumab | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of ranibizumab (0.5 mg per dose) | Intervention Type: DRUG; Name: Intravitreal injection of bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab (0.5 mg per dose); Assigned to Arm(s): Ranibizumab
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 2, 3 | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): 1, 2

Answer: C